Skip to main content

Newsroom press releases

13/10/26 - 13:00

Diasorin obtained FDA approval for Human Parvovirus B19 IgM and IgG on the Liaison XL (334.34 KB)
Products Immunodiagnostic

02/10/26 - 14:22

Margherita Sacerdoti appointed Investor Relations & ESG Senior Director at Diasorin (151.77 KB)
Other

31/07/26 - 12:50

Revenue and EBITDA Supported by Strong Q2 Growth in the First Half of the Year. 2026 Guidance Confirmed. (277.39 KB)
Financial Data

19/06/26 - 15:45

Diasorin Announces FDA 510(K) Clearance and CLIA Waiver for the LIAISON NES Group A Streptococcus (GAS) Assay (174.02 KB)
Products Molecular

20/05/26 - 11:16

Diasorin Board of Directors approves the 2026-2030 Business Plan (246.32 KB)
Financial Data

19/05/26 - 19:23

Diasorin Receives 510(K) Clearance for Fully Customizable LIAISON PLEX Gastrointestinal Flex Assay (179.61 KB)
Products Molecular

08/05/26 - 17:54

Revenues and EBITDA in line with the expected quarterly revenue trend and impacted by a weak flu season. 2026 Guidance confirmed (256.38 KB)
Financial Data

04/05/26 - 17:45

Diasorin Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President (158.42 KB)
Other

29/04/26 - 15:52

Shareholders' Meeting 2026 (166.06 KB)
Other

07/04/26 - 10:05

Communication on total amount of voting rights (7 April 2026) (225.44 KB)
Other

25/03/26 - 12:04

Publication of the document for the Ordinary Shareholders' Meeting scheduled on April 29, 2026 (181.97 KB)
Financial Disclosures

20/03/26 - 17:44

Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024 (349.08 KB)
Financial Data

19/03/26 - 9:47

Diasorin signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care platform (234.16 KB)
Other

24/02/26 - 7:06

Diasorin introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with QIAGEN (154.8 KB)
Products Immunodiagnostic

03/02/26 - 12:13

Diasorin submits LIAISON NES Group A Strep molecular test to the U.S. FDA for 510(k) Clearance and CLIA Waiver (130.94 KB)
Products Molecular

29/01/26 - 7:03

Diasorin has been granted De novo authorization in the U.S. for the First Fully Automated Laboratory Test for Hepatitis Delta Virus (HDV) on the LIAISON XL (128.56 KB)
Products Immunodiagnostic

27/01/26 - 16:05

The Shareholders' meeting authorized the purchase of treasury shares, approved the amendment of art. 5 of the articles of association and authorized the cancellation of treasury shares. The Board approved the launch of the buyback plan. (120.91 KB)
Other

26/01/26 - 7:09

Diasorin signs exclusive distribution agreement for the LIAISON NES® molecular point‑of‑care platform and the Flu A/B, RSV & Covid‑19 panel (131.63 KB)
Products Molecular

23/01/26 - 17:49

Succession in the role of Group Chief Financial Officer of Diasorin. Alberto Donati appointed new Group Chief Financial Officer. (108.99 KB)
Other

08/11/13 - 1:00

The Board of Directors approves the Q3'13 Results (766.57 KB)
Financial Data

29/10/13 - 1:00

DiaSorin signes a 5-year agreement with Roche (432.42 KB)
Acquisition / Partnership

25/10/13 - 2:00

DiaSorin launches the EHEC Toxins test on stool samples (610.05 KB)
Products Immunodiagnostic

10/10/13 - 2:00

DiaSorin launches the test for IgG to Trypanosoma Cruzi (Chagas) (615.28 KB)
Products Immunodiagnostic

24/09/13 - 2:00

DiaSorin launches the hCG test on its LIAISON XL in the US (599.75 KB)
Products Immunodiagnostic

01/08/13 - 2:00

The Board of Directors approves the results for the H1 '13 (386.67 KB)
Financial Data

24/07/13 - 2:00

DiaSorin launches the new test for Toxoplasmosis on LIAISON IAM (490.89 KB)
Products

11/07/13 - 2:00

DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in Brazil (113.84 KB)
Products Immunodiagnostic

28/06/13 - 2:00

DiaSorin launches the test of Chlamydia Trachomatis IgG and IgA on LIAISON (78.13 KB)
Products Immunodiagnostic

20/06/13 - 2:00

DiaSorin launches the new test for Parvovirus on LIAISON IAM (488.24 KB)
Products Immunodiagnostic

10/05/13 - 2:00

The Board of Directors approves the results for Q1'13 (763.61 KB)
Financial Data

02/05/13 - 2:00

Compensation Commitee-Errata corrige (179.38 KB)
Financial Data

22/04/13 - 2:00

Shareholders' meeting approves FY Results 2012 (57.22 KB)
Financial Data

17/04/13 - 2:00

FDA approves the Aldosterone assay (439.58 KB)
Products Immunodiagnostic

02/04/13 - 2:00

DiaSorin signs an agreement with Seegene (243.64 KB)
Acquisition / Partnership

08/03/13 - 1:00

The BoD approves FY 2012 results (477.24 KB)
Financial Data

07/03/13 - 1:00

Notification of changes in share capital (46.86 KB)
Financial Data

07/03/13 - 1:00

Notice availability By-Laws (36.87 KB)
Financial Data

07/02/13 - 1:00

Clostridium difficile on LIAISON (available outside the US and Canada only) (79.83 KB)
Products Immunodiagnostic

07/02/13 - 1:00

Notification of changes in share capital (46.89 KB)
Financial Data

07/02/13 - 1:00

Notice availability By-Laws (139.13 KB)
Financial Data

30/01/13 - 1:00

The Board of Directors approves the results for the FY '12 (477.24 KB)
Financial Data

29/01/13 - 1:00

Aldosterone on LIAISON (available outside the US and Canada only) (76.47 KB)
Products Immunodiagnostic